SSTR2 and neoplasm: Here, SSTR2-antagonists, like the theranostic pair 68Ga-satoreotide trizoxetan/177Lu-satoreotide tetraxetan (68Ga-SSO120/177Lu-SSO110, previously 68Ga-OPS-202/177Lu-OPS-201 or 68Ga-NODAGA-JR11/177Lu-DOTA-JR11), offer higher tumor uptake and prolonged retention times, potentially due to their binding to SSTRs in both active and inactive states 14.